Vitamin D analogs for secondary hyperparathyroidism: What does the future hold?

Journal of Steroid Biochemistry and Molecular Biology

Volumn 103, Issue 3-5, 2007, Pages 578-583

  Brown, Alex J ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1ALPHA HYDROXY 2 METHYLENE 19 NORBISHOMOPREGNACALCIFEROL; 22 OXACALCITRIOL; 9,10 SECOCHOLESTA 5,7,10(19),16 TETRAEN 23 YNE 1,3,25 TRIOL; ALFACALCIDOL; CALCITRIOL; CALCIUM; CINACALCET; DOXERCALCIFEROL; FALECALCITRIOL; PARATHYROID HORMONE; PARICALCITOL; PHOSPHATE; PHOSPHATE BINDING AGENT; UNCLASSIFIED DRUG; VITAMIN D; VITAMIN D DERIVATIVE;

ARTICLE; BLOOD VESSEL CALCIFICATION; BONE GROWTH; CALCIFICATION; CLINICAL TRIAL; DISEASE CLASSIFICATION; DRUG CLEARANCE; DRUG HALF LIFE; DRUG MECHANISM; DRUG SELECTIVITY; DRUG STRUCTURE; GENETIC TRANSCRIPTION; HORMONE RELEASE; HUMAN; HYPERCALCEMIA; KIDNEY DISEASE; MORBIDITY; MORTALITY; NONHUMAN; PARATHYROID GLAND; PARATHYROID HYPERPLASIA; RISK FACTOR; SECONDARY HYPERPARATHYROIDISM; SURVIVAL;

ANIMALS; HUMANS; HYPERPARATHYROIDISM, SECONDARY; VITAMIN D;

EID: 33947225707     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2006.12.089     Document Type: Article

References (47)

1. Slatopolsky E., Brown A.J., and Dusso A. Pathogenesis of secondary hyperparathyroidism. Kidney Int. 73 (1999) S14-S19
2. Martin K.J., Olgaard K., Coburn J.W., Coen G.M., Fukagawa M., Langman C., Malluche H.H., McCarthy J.T., Massry S.G., Mehls O., Salusky I.B., Silver J.M., Smogorzewski M.T., Slatopolsky E.M., and McCann L. Diagnosis, assessment, and treatment of bone turnover abnormalities in renal osteodystrophy. Am. J. Kidney Dis. 43 (2004) 558-565
3. 3. J. Nutr. Sci. Vitaminol. 35 (1989) 529-533
4. Dusso A.S., Negrea L., Gunawardhana S., Lopez-Hilker S., Finch J., Mori T., Nishii Y., Slatopolsky E., and Brown A.J. On the mechanisms for the selective action of vitamin D analogs. Endocrinology 128 (1991) 1687-1692
5. Brown A.J., Finch J., Grieff M., Ritter C., Kubodera N., Nishii Y., and Slatopolsky E. The mechanism for the disparate actions of calcitriol and 22-oxacalcitriol in the intestine. Endocrinology 133 (1993) 1158-1164
6. 3, in rats. J. Biochem. 115 (1994) 373-380
7. Brown A.J., Finch J.L., Lopez-Hilker S., Dusso A., Ritter C., Pernalete N., and Slatopolsky E. New active analogues of vitamin D with low calcemic activity. Kidney Int. 29 Suppl. 29 (1990) S22-S27
8. 3, determined by micro-autoradiography. Nephol. Dial. Transplant. 17 Suppl. 10 (2002) 53-57
9. Takeyama K., Masuhiro Y., Fuse H., Endoh H., Murayama A., Kitanaka S., Suzawa M., Yanagisawa J., and Kato S. Selective interaction of vitamin D receptor with transcriptional coactivators by a vitamin D analog. Mol. Cell. Biol. 19 (1999) 1049-1055
10. Akizawa T., Suzuki M., Akiba T., Nishizawa Y., Ohashi Y., Ogata E., Slatopolsky E., and Kurokawa K. Long-term effect of 1,25-dihydroxy-22-oxavitamin D(3) on secondary hyperparathyroidism in haemodialysis patients. One-year administration study. Nephrol. Dial. Transplant. 17 Suppl. 10 (2002) 28-36
11. Hayashi M., Tsuchiya Y., Itaya Y., Takenaka T., Kobayashi K., Yoshizawa M., Nakamura R., Monkawa T., and Ichihara A. Comparison of the effects of calcitriol and maxacalcitol on secondary hyperparathyroidism in patients on chronic haemodialysis: a randomized prospective multicentre trial. Nephrol. Dial. Transplant. 19 (2004) 2067-2073
12. 2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. J. Am. Soc. Nephrol. 9 (1998) 1427-1432
13. 2. Am. J. Kidney Dis. 32 (1998) S61-S66
14. Llach F., and Yudd M. Paricalcitol in patients with calcitriol-resistent secondary hyperparathyroidism. Am. J. Kidney Dis. 38 (2001) S45-S50
15. Sprague S.M., Lerma E., McCormmick D., Abraham M., and Batlle D. Suppression of parathyroid hormone secretion in hemodialysis patients: comparison of paricalcitol with calcitriol. Am. J. Kidney Dis. 38 (2001) S51-S56
16. Sprague S.M., Llach F., Amdahl M., Taccetta C., and Batlle D. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int. 63 (2003) 1483-1490
17. 3 in the rat. Proc. Soc. Exp. Biol. Med. 178 (1985) 432-436
18. 2 in hemodialysis patients with moderate to severe secondary hyperparathyroidism. Kidney Int. 51 (1997) 317-323
19. 2 is effective and safe for the suppression of secondary hyperparathyroidism in haemodialysis patients. Nephrol. Dial. Transplant. 3 (1998) 68-72
20. 2) in dialysis patients with secondary hyperparathyroidism: a sequential comparison. Am. J. Kidney Dis. 37 (2001) 532-543
21. Slatopolsky E., Cozzolino M., and Finch J.L. Differential effects of 19-nor-1,25-(OH)(2)D(2) and 1alpha-hydroxyvitamin D(2) on calcium and phosphorus in normal and uremic rats. Kidney Int. 62 (2002) 1277-1284
22. Reinhart G.A., Fryer R.M., Koch K.A., Bolin A.L., Rakestraw P.A., Noonan W.T., Dixon D.B., Rose A.E., Osinski M.A., and Wu-wong J.R. Differential effects of paricalcitol and doxercalciferol on serum PTH and ionized calcium in uremic rats with established secondary hyperparathyroidism. J. Am. Soc. Nephrol. 16 (2005) 495A
23. Zisman A.L., Ghantous W., Schinleber P., Roberts L., and Sprague S.M. Inhibition of parathyroid hormone: a dose equivalency study of paricalcitol and doxercalciferol. Am. J. Nephrol. 25 (2005) 591-595
24. Coyne D.W., Grieff M., Ahya S.N., Giles K., Norwood K., and Slatopolsky E. Differential effects of acute administration of 19-Nor-1,25-dihydroxy-vitamin D2 and 1,25-dihydroxy-vitamin D3 on serum calcium and phosphorus in hemodialysis patients. Am. J. Kidney Dis. 40 (2002) 1283-1288
25. Komuro S., Sato M., and Kanamaru H. Disposition and metabolism of F6-1alpha,25(OH)2 vitamin D3 and 1alpha,25(OH)2 vitamin D3 in the parathyroid glands of rats dosed with tritium-labeled compounds. Drug Metab. Dispos. 31 (2003) 973-978
26. Lippuner K., Perrelet R., Casez J.P., Popp A., Uskokovic M.R., and Jaeger P. 1,25-(OH)2-16ene-23yne-D3 reduces secondary hyperparathyroidism in uremic rats with little calcemic effect. Horm. Res. 61 (2004) 7-16
27. Brown A.J., Ritter C.S., Weiskopf A.S., Vouros P., Sasso G.J., Uskokovic M.R., Wang G., and Reddy G.S. Isolation and identification of 1alpha-hydroxy-3-epi-vitamin D(3), a potent suppressor of parathyroid hormone secretion. J. Cell. Biochem. 96 (2005) 569-578
28. Plum L.A., Prahl J.M., Ma X., Sicinski R.R., Gowlugari S., Clagett-Dame M., and DeLuca H.F. Biologically active noncalcemic analogs of 1alpha,25-dihydroxyvitamin D with an abbreviated side chain containing no hydroxyl. Proc. Natl. Acad. Sci. USA 101 (2004) 6900-6904
29. Slatopolsky E., Finch J., Plum L.A., Clagett-Dame M., Sicinski R.F., and DeLuca H.F. A new vitamin D analog without calcemic and phosphatemic effects. J. Am. Soc. Nephol. 14 (2003) (abstract)
30. Martinez I., Saracho R., Montenegro J., and Llach F. A deficit of calcitriol synthesis may not be the initial factor in the pathogenesis of secondary hyperparathyroidism. Nephrol. Dial. Transplant. 11 (1996) 22-28
31. Ho L.T., and Sprague S.M. Renal osteodystrophy in chronic renal failure. Semin. Nephrol. 22 (2002) 488-493
32. Healy M.D., Malluche H.H., Goldstein D.A., Singer F.R., and Massry S.G. Effects of long-term therapy with calcitriol in patients with moderate renal failure. Arch. Intern. Med. 140 (1980) 1030-1033
33. Baker L.R., Abrams L., Roe C.J., Faugere M.C., Fanti P., Subayti Y., and Malluche H.H. 1,25(OH)2D3 administration in moderate renal failure: a prospective double-blind trial. Kidney Int. 35 (1989) 661-669
34. Coburn J.W., Maung H.M., Elangovan L., Germain M.J., Lindberg J.S., Sprague S.M., Williams M.E., and Bishop C.W. Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4. Am. J. Kidney Dis. 43 (2004) 877-890
35. Coyne D., Acharya M., Qui P., Abboud H., Batlle D., Rosansky S., Fadem S., Levine B., Williams L., Andress D.L., and Sprague S.M. Paricalcitol capsule for treatment of secondary hyperparathyroidism in stages 3 and 4 CKD. Am. J. Kidney Dis. 47 (2006) 263-276
36. 3-1α-hydroxylase expression in normal and pathological parathyroid glands. J. Clin. Endocrinol. Metab. 87 (2002) 2967-2972
37. 3 24-hydroxylase in parathyroid tumors-new prospects for treatment of hyperparathyroidism with vitamin D. J. Clin. Endocrinol. Metab. 87 (2002) 5826-5829
38. 3. J. Am. Soc. Nephrol. 16 (2005) 750A
39. Slatopolsky E.A., Burke S.K., Dillon M.A., and The RenaGel Study Group. RenaGel, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. Kidney Int. 55 (1999) 299-307
40. Albaaj F., and Hutchison A.J. Lanthanum carbonate (Fosrenol): a novel agent for the treatment of hyperphosphataemia in renal failure and dialysis patients. Int. J. Clin. Pract. 59 (2005) 1091-1096
41. Block G.A., Martin K.J., de Francisco A.L., Turner S.A., Avram M.M., Suranyi M.G., Hercz G., Cunningham J., Abu-Alfa A.K., Messa P., Coyne D.W., Locatelli F., Cohen R.M., Evenepoel P., Moe S.M., Fournier A., Braun J., McCary L.C., Zani V.J., Olson K.A., Drueke T.B., and Goodman W.G. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N. Engl. J. Med. 350 (2004) 1516-1525
42. Goodman W.G. Calcimimetics: a remedy for all problems of excess parathyroid hormone activity in chronic kidney disease?. Curr. Opin. Nephrol. Hypertens. 14 (2005) 355-360
43. Teng M., Wolf M., Lowrie E., Ofsthun N., Lazarus M., and Thadhani R. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N. Engl. J. Med. 349 (2003) 446-456
44. Teng M., Wolf M., Ofsthun M.N., Lazarus J.M., Hernan M.A., Camargo Jr. C.A., and Thadhani R. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J. Am. Soc. Nephrol. 16 (2005) 1115-1125
45. Tentori F., Hunt W.C., Stidley C.A., Rohrsceib M.R., Meyer K.B., and Zager P.G. Survival among hemodialysis patients receiving intravenous doxercalciferol and paricalcitol versus calcitriol. J. Am. Soc. Nephol. 16 (2005) 279A
46. Dobrez D.G., Mathes A., Amdahl M., Marx S.E., Melnick J.Z., and Sprague S.M. Paricalcitol-treated patients experience improved hospitalization outcomes compared with calcitriol-treated patients in real-world clinical settings. Nephrol. Dial. Transplant. 19 (2004) 1174-1181
47. Tentori F., Hunt W.C., Rohrsceib M.R., Stidley C.A., Meyer K.B., and Zager P.G. Decreased odds of hospitalization among hemodialysis patients receiving doxercalciferol and paricalcitol versus calcitriol. J. Am. Soc. Nephrol. 16 (2005) 279A